Nalmefene long-acting injectable (AP007) for the treatment of opioid use disorder
Ended Cooperative Agreement Awarded Last action
- Award ID
- UG3DA048745
- Recipient
-
Emergent Product Development Gaithersburg Inc. UEI CNPVCR8DK7M8
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,354,906
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $6,354,906 |
Quick answers
Who received award UG3DA048745?
UG3DA048745 was awarded to Emergent Product Development Gaithersburg Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2019.
How much is award UG3DA048745 worth?
$6,354,906 has been obligated on UG3DA048745.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award